HOWL Werewolf Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HOWL

Price (delayed)

$6.07

Market cap

$263.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$175.86M

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its ...

Highlights
Werewolf Therapeutics's debt has decreased by 3.7% YoY
HOWL's EPS is up by 34% YoY but it is down by 3.8% from the previous quarter
The company's net income rose by 18% YoY but it fell by 11% QoQ
The gross profit has contracted by 22% YoY and by 19% from the previous quarter
Werewolf Therapeutics's revenue has decreased by 22% YoY and by 19% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://werewolftx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of HOWL
Market
Shares outstanding
43.46M
Market cap
$263.77M
Enterprise value
$175.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.21
Price to sales (P/S)
15.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.84
Earnings
Revenue
$16.22M
EBIT
-$37.44M
EBITDA
-$34.02M
Free cash flow
-$38.72M
Per share
EPS
-$1.09
Free cash flow per share
-$0.93
Book value per share
$2.75
Revenue per share
$0.39
TBVPS
$4.27
Balance sheet
Total assets
$177.6M
Total liabilities
$60.01M
Debt
$51.27M
Equity
$117.59M
Working capital
$121.07M
Liquidity
Debt to equity
0.44
Current ratio
6.71
Quick ratio
6.6
Net debt/EBITDA
2.58
Margins
EBITDA margin
-209.7%
Gross margin
100%
Net margin
-256.3%
Operating margin
-280.1%
Efficiency
Return on assets
-23.3%
Return on equity
-36.2%
Return on invested capital
-51.6%
Return on capital employed
-23.9%
Return on sales
-230.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HOWL stock price

How has the Werewolf Therapeutics stock price performed over time
Intraday
-0.16%
1 week
-10.07%
1 month
0.83%
1 year
131.68%
YTD
57.25%
QTD
-6.33%

Financial performance

How have Werewolf Therapeutics's revenue and profit performed over time
Revenue
$16.22M
Gross profit
$16.22M
Operating income
-$45.44M
Net income
-$41.58M
Gross margin
100%
Net margin
-256.3%
The company's operating margin fell by 38% QoQ and by 10% YoY
Werewolf Therapeutics's net margin has decreased by 37% QoQ and by 6% YoY
The gross profit has contracted by 22% YoY and by 19% from the previous quarter
Werewolf Therapeutics's revenue has decreased by 22% YoY and by 19% from the previous quarter

Growth

What is Werewolf Therapeutics's growth rate over time

Valuation

What is Werewolf Therapeutics stock price valuation
P/E
N/A
P/B
2.21
P/S
15.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.84
HOWL's EPS is up by 34% YoY but it is down by 3.8% from the previous quarter
HOWL's price to book (P/B) is 70% higher than its last 4 quarters average of 1.3
The equity has grown by 6% from the previous quarter but it has contracted by 2.9% YoY
HOWL's price to sales (P/S) is 102% higher than its last 4 quarters average of 7.7
Werewolf Therapeutics's revenue has decreased by 22% YoY and by 19% from the previous quarter

Efficiency

How efficient is Werewolf Therapeutics business performance
HOWL's ROIC has soared by 72% YoY but it is down by 5% QoQ
HOWL's ROS is down by 34% from the previous quarter but it is up by 4.2% YoY
Werewolf Therapeutics's return on assets has increased by 19% YoY but it has decreased by 14% QoQ
Werewolf Therapeutics's return on equity has decreased by 12% QoQ but it has increased by 10% YoY

Dividends

What is HOWL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOWL.

Financial health

How did Werewolf Therapeutics financials performed over time
The total assets is 196% higher than the total liabilities
The company's total liabilities fell by 19% YoY and by 5% QoQ
The quick ratio has declined by 18% year-on-year and by 6% since the previous quarter
Werewolf Therapeutics's debt is 56% lower than its equity
The equity has grown by 6% from the previous quarter but it has contracted by 2.9% YoY
HOWL's debt to equity is down by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.